PROTACpedia
The search can be performed by various parameters such as Target name, UniProt ID, SMILES substructure or by various details regarding a publication.
Note that it is possible to narrow down the search results by querying several fields simultaneously.

The resulting PROTAC images are color coded: green - E3 binder, red - linker, blue - target binding ligand.
If you find this web server of interest, please also try PRosettaC.
Gene or Target name
UniProt Id
Ligand name
E3 Ligase
E3 Binder
PROTAC SMILES (substructure)
PROTAC Name
Author
Year
Pubmed or Patent number
Curator
Algorithm and overview: Nir London (nir.london@weizmann.ac.il)
Server: Jaime Prilusky (jaime.prilusky@weizmann.ac.il)
17 Representative
+68 Active PROTACs
+6 Inactive PROTACs
 DetailsDC50DmaxSource
= 430 nM= 95 % DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015 Jun 19;348(6241):1376-81. PMID:25999370 DOI:10.1126/science.aab1433
< 1 nM~ 100 % Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. PMID:26051217 DOI:10.1016/j.chembiol.2015.05.009
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 Mar 13. PMID:28288108 DOI:10.1038/nchembio.2329
< 1 nM= 100 % Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. PMID:28339196 DOI:10.1021/acs.jmedchem.6b01816
< 1 nM= 100 % Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. PMID:28339196 DOI:10.1021/acs.jmedchem.6b01816
~ 3 nM Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. PMID:28339196 DOI:10.1021/acs.jmedchem.6b01816
~ 10 nM Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. PMID:28339196 DOI:10.1021/acs.jmedchem.6b01816
< 10 nM= 100 % Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. PMID:28339196 DOI:10.1021/acs.jmedchem.6b01816
= 0.20 μM> 90 % A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
= 0.059 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
= 0.083 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
= 0.24 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
= 0.45 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
= 0.46 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
= 0.49 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
= 0.63 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
> 5 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
> 5 μM A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461. PMID:28378579 DOI:10.1021/acs.jmedchem.6b01781
< 2.5 nM> 98 % Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. PMID:28595007 DOI:10.1021/acs.jmedchem.6b01912
< 1 nM> 83 % Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. PMID:28595007 DOI:10.1021/acs.jmedchem.6b01912
< 4 nM> 97 % Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. PMID:28595007 DOI:10.1021/acs.jmedchem.6b01912
~ 7.9 nM> 90 % Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. PMID:28595007 DOI:10.1021/acs.jmedchem.6b01912
~ 7.9 nM> 90 % Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. PMID:28595007 DOI:10.1021/acs.jmedchem.6b01912
~ 0.1 μM Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. PMID:28595007 DOI:10.1021/acs.jmedchem.6b01912
< 0.1 μM> 93 % Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem. 2018 Jan 25;61(2):504-513. PMID:28595007 DOI:10.1021/acs.jmedchem.6b01912
< 3 nM= 100 % 3-Fluoro-4-hydroxyprolines: Synthesis, conformational analysis and stereoselective recognition by the VHL E3 ubiquitin ligase for targeted protein degradation. J Am Chem Soc. 2018 Jun 27. PMID:29949369 DOI:10.1021/jacs.8b05807
< 30 nM= 99 % 3-Fluoro-4-hydroxyprolines: Synthesis, conformational analysis and stereoselective recognition by the VHL E3 ubiquitin ligase for targeted protein degradation. J Am Chem Soc. 2018 Jun 27. PMID:29949369 DOI:10.1021/jacs.8b05807
< 0.5 nM= 100 % Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018 Aug 9;61(15):6685-6704. PMID:30019901 DOI:10.1021/acs.jmedchem.8b00506
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018 Aug 9;61(15):6685-6704. PMID:30019901 DOI:10.1021/acs.jmedchem.8b00506
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018 Aug 9;61(15):6685-6704. PMID:30019901 DOI:10.1021/acs.jmedchem.8b00506
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018 Aug 9;61(15):6685-6704. PMID:30019901 DOI:10.1021/acs.jmedchem.8b00506
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018 Aug 9;61(15):6685-6704. PMID:30019901 DOI:10.1021/acs.jmedchem.8b00506
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018 Aug 9;61(15):6685-6704. PMID:30019901 DOI:10.1021/acs.jmedchem.8b00506
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018 Aug 9;61(15):6685-6704. PMID:30019901 DOI:10.1021/acs.jmedchem.8b00506
= 32 nM= 98 % MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. Cancer Res. 2019 Jan 1;79(1):251-262. PMID:30385614 DOI:10.1158/0008-5472.CAN-18-2918
= 0.32 nM= 100 % A novel cereblon modulator for targeted protein degradation. Eur J Med Chem. 2019 Mar 15;166:65-74. PMID:30684871 DOI:10.1016/j.ejmech.2019.01.023
= 3.3 nM= 100 % A novel cereblon modulator for targeted protein degradation. Eur J Med Chem. 2019 Mar 15;166:65-74. PMID:30684871 DOI:10.1016/j.ejmech.2019.01.023
= 63 % A novel cereblon modulator for targeted protein degradation. Eur J Med Chem. 2019 Mar 15;166:65-74. PMID:30684871 DOI:10.1016/j.ejmech.2019.01.023
= 36 % A novel cereblon modulator for targeted protein degradation. Eur J Med Chem. 2019 Mar 15;166:65-74. PMID:30684871 DOI:10.1016/j.ejmech.2019.01.023
> 50 % Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications. ACS Chem Biol. 2019 Nov 15;14(11):2430-2440. PMID:31059647 DOI:10.1021/acschembio.8b01083
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. Nat Chem Biol. 2019 Jul;15(7):747-755. PMID:31209351 DOI:10.1038/s41589-019-0304-8
< 5 nM~ 100 % Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells. Biochem Biophys Res Commun. 2020 Jan 22;521(4):833-839. PMID:31708096 DOI:10.1016/j.bbrc.2019.11.007
< 125 nM= 90 % Structure-Based Design of a Macrocyclic PROTAC. Angew Chem Int Ed Engl. 2019 Nov 19. PMID:31746102 DOI:10.1002/anie.201914396
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Bioorg Med Chem. 2020 Jan 1;28(1):115181. PMID:31767403 DOI:10.1016/j.bmc.2019.115181
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Bioorg Med Chem. 2020 Jan 1;28(1):115181. PMID:31767403 DOI:10.1016/j.bmc.2019.115181
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Bioorg Med Chem. 2020 Jan 1;28(1):115181. PMID:31767403 DOI:10.1016/j.bmc.2019.115181
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Bioorg Med Chem. 2020 Jan 1;28(1):115181. PMID:31767403 DOI:10.1016/j.bmc.2019.115181
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Bioorg Med Chem. 2020 Jan 1;28(1):115181. PMID:31767403 DOI:10.1016/j.bmc.2019.115181
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. PMID:31813613 DOI:10.1016/j.bmc.2019.115228
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
PHOTACs enable optical control of protein degradation. Sci Adv. 2020 Feb 21;6(8):eaay5064. PMID:32128406 DOI:10.1126/sciadv.aay5064
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative. Bioorg Chem. 2020 Jun;99:103817. PMID:32361153 DOI:10.1016/j.bioorg.2020.103817
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative. Bioorg Chem. 2020 Jun;99:103817. PMID:32361153 DOI:10.1016/j.bioorg.2020.103817
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative. Bioorg Chem. 2020 Jun;99:103817. PMID:32361153 DOI:10.1016/j.bioorg.2020.103817
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative. Bioorg Chem. 2020 Jun;99:103817. PMID:32361153 DOI:10.1016/j.bioorg.2020.103817